Serum lysophospholipase D/autotaxin may be a new nutritional assessment marker: study on prostate cancer patients

Serum lysophospholipase D/autotaxin may be a new nutritional assessment marker: study on prostate cancer patients
复制标题

DOI:
10.1258/000456307782268147
复制
发表时间:
2007-11-01
影响因子:
2.2
通讯作者:
Yatomi, Yutaka
Yatomi, Yutaka
中科院分区:
医学4区
文献类型:
--
作者:
Nakamura, Kazuhiro;Takeuchi, Takumi;Yatomi, Yutaka

文献摘要

被引文献

相似文献

背景:现已证实,生物活性脂类溶血磷脂酸(LPA)与肿瘤的发生、发展和转移有关,前列腺癌也不例外。LPA主要在血清和血浆中通过溶血磷脂酶D(LysoPLD)的作用由溶血磷脂转化而产生,这与最初作为一种肿瘤细胞运动刺激因子分离出来的可溶性自体趋化因子(ATX)相同。方法采用溶血磷脂酰胆碱释放法检测前列腺癌患者血清溶血磷脂酶活性,并与前列腺特异性抗原(PSA)及常规营养指标进行比较。结果前列腺癌患者血清溶血磷脂酶活性与正常对照组无显著差异,与前列腺癌患者血清溶血磷脂酶活性无相关性。而前列腺癌患者术后溶血磷脂酶D/ATX活性下降,似可反映前列腺癌患者术后受损情况或营养状况。结论血清溶血磷脂酶D/ATX活性虽不能作为前列腺癌的标志物,但有望成为反映前列腺癌患者营养状况的新指标。
Background It is now established that the bioactive lipid lysophosphatidic acid (LPA) contributes to cancer initiation, progression and metastasis, including those of prostate cancer. LPA is produced in the serum and plasma mainly by conversion from lysophospholipids through the action of lysophospholipase D (lysoPLD), which is identical to the soluble form of autotaxin (ATX) originally isolated as a tumour cell motility-stimulating factor. In this study, we evaluated the usefulness of lysoPLD/ ATX activity as a diagnostic marker.Methods The serum lysoPLD activity, assessed by measuring choline liberation from the substrate lysophosphatidylcholine, was measured in patients with prostate cancer and compared with the concentrations of prostate-specific antigen (PSA) and conventional nutritional assessment markers.Results The serum lysoPLD activity in prostate cancer patients was not statistically different from that in the controls, Consistent with this, there was no correlation between the serum lysoPLD activity and the serum PSA concentrations. However, the lysoPLD/ATX activity did decrease after operation in the prostate cancer patients and seemed to reflect the postoperative damage or the nutritional status.Conclusions We postulate that while the serum lysoPLD/ATX may not be a marker of prostate cancer, it promises to instead be a new marker of nutritional status.